Objective: Our aim was to identify natural products with anti-tubercular activity.
Introduction
Tuberculosis remains a global health problem, with an increasing number of new cases (10.4 million in 2015) and an increasing problem of drug resistance [1] . New therapeutic agents which act against novel bacterial targets are needed to supplement and supplant the current drugs. Therefore there is great interest in finding new chemical matter that has activity against the causative agent, Mycobacterium tuberculosis. A large effort has been expended to examine small molecule libraries as starting point for drug discovery [2, 3] . Less attention has been paid to natural products as starting points for a discovery program. We were interested in expanding chemical diversity to identify novel inhibitors which could be used either as starting points for a drug discovery program or as probes to identify novel targets.
Main text
A phenotypic screen to identify compounds with activity against M. tuberculosis using the MSD collection of purified natural products was initiated. A small set (~ 500) of natural products for activity against M. tuberculosis H37Rv-LP (ATCC 25618) expressing a red fluorescent protein were tested [4] [5] [6] . Compounds were tested at a single concentration of 20 µM. Growth was measured by fluorescence after 5 days of aerobic culture in Middlebrook 7H9 medium supplemented with 10% v/v OADC (oleic acid, albumin, d-glucose, catalase; Becton-Dickinson) and 0.05% w/v Tween 80 at 37 °C in 384-well plates. Growth inhibition was calculated with reference to controls (DMSO only). Within this screen, hits were defined as having > 30% inhibition of growth. Hits were confirmed by testing compounds in a dose response, using two readouts for growth-OD 590 and fluorescence (Ex 560/Em 590) [4] [5] [6] From these experiments, MSD-453 confirmed as a hit and further analogs based on similarity searches were ordered and tested. The initial hit, a cyclic hexapeptide,
(compound 1) had good activity against M. tuberculosis, with an MIC 90 of 2.3 µM (Table 1) . Several natural congeners (2-4) and semi-synthetic and synthetic analogs (5-16) were available from the MSD sample library and were tested for activity against replicating M. tuberculosis under aerobic conditions in liquid medium. Structural identities and purity of the compounds were verified prior to anti-tubercular testing. Four other analogs (2-5) exhibited intermediate inhibitory potencies (MIC 90 of 2.8-8.9 μM), whereas eleven compounds (6-16) showed no inhibitory activity (MIC 90 > 20 µM).
Although the dataset of compounds tested are limited, some elements of the structure-activity relationship (SAR) (Fig. 1) have been determined. Replacement of the N-hydroxyleucine with N-hydroxyisoleucine resulted in similar activity (2, MIC 90 = 2.8 µM). Replacement of the phenylalanine with a valine reduced the activity slightly by three to fourfold (3, MIC 90 = 8.9 µM). Similar reduced activity was seen after a double substitution of N-methylphenylalanine and phenylalanine with isoleucine and leucine (4, MIC 90 = 7.3 µM). An N-alkyl-ketone in place of N-hydroxyleucine was tolerated, but reduced the biological activity by threefold (5, MIC 90 = 8.2 µM), demonstrating that the N-hydroxyl group at that position is not critical. In contrast, the piperazic acids (Piz) were critical for activity of the molecule, since several tetrahydropiperazic (∆Piz) acid derivatives (6-12) and the pipecolic acid (Pip) (13 and 15) analog resulted in loss of antitubercular activity. O-Alkylation of the N-hydroxyleucine with an acetic acid or acetic acid ester abrogated activity (13) (14) . The combined replacement of N-methylphenylalanine with norvaline and phenylalanine with leucine also removed activity (16, MIC 90 > 20 μM). Based on these analogs, we were able to determine some limited structure-activity relationship (Fig. 1) . Although the compounds were not as potent as rifampicin, they did have good activity, with a dynamic SAR ranging from low micromolar to inactive (> 20 µM).
The original hit molecule, MSD-453, along with several congeners [7] [8] [9] [10] and synthetic analogs [8] [9] [10] [11] [12] , were originally identified as sub-micromolar to low nanomolar oxytocin receptor antagonists. M. tuberculosis does not have a homolog of this receptor; thus, this series appears to have a different target in the pathogen. In an attempt to identify the M. tuberculosis biochemical target, resistant mutants to two of the compounds were isolated. The potency of each compound on Middlebrook 7H10 medium containing 10% v/v OADC supplement was measured. MIC 99 values were determined by the serial proportion method and defined as the minimum concentration required to prevent 99% growth on solid medium [13] . Under these incubation conditions, the MIC 99 was 1.6 and 0.8 µM for MSD-045 and MSD-099 respectively (Table 2 ). Resistant mutants MIC 90 were determined against aerobically-cultured M. tuberculosis in liquid culture after 5 days of growth [5] . Growth inhibition curves were plotted using the Levenberg-Marquardt algorithm and the concentration that resulted in 90% inhibition of growth was determined (MIC 90 ). MIC 90 were determined a minimum of two times for active compounds. Data are average ± standard deviation were isolated on Middlebrook 7H10 plus 10% v/v OADC at 5X MIC of each compound after 3-4 weeks growth [14] . Colonies were tested for MIC 99 on solid medium to confirm resistance (Table 2 ). In this longer term assay on solid media both compounds showed better potency than when tested for shorter time (5 days) assay in liquid media (Table 1) . Although nine confirmed resistant isolates were subjected to whole genome sequencing [15] , no mutations were observed in 8 of the strains. Strain LP-0458686-RM1 had two mutations, one in gap (Rv1436) and one in Rv1543, but these were not observed in any of the other eight strains. Thus no genotypic explanation for the observed resistance was determined. In this case, the resistance phenotype could be due to epigenetic phenomena.
In conclusion, a series of cyclic natural product peptides with activity against M. tuberculosis, which could form the basis of further exploratory work including target identification, are disclosed. Future work to identify the intracellular target would assist in further development of this class of molecules.
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